Extensive Arterial Thrombosis in Covid-19

The patient had no history of venous or arterial clots, no known vasculopathy, minimal underlying atherosclerosis, no personal or family history of hypercoagulable disease, no aortic compression as nidus for thrombus formation, and evaluation for malignancy has been negative to date. Heightened clinical vigilance is needed for early identification of this potentially serious complication of Covid-19 to facilitate prompt intervention targeting limb salvage,3–6 Further research is needed to determine the role of hypercoagulability in Covid-19, and to identify strategies to prevent and treat venous and arterial thrombosis in this setting.Disclosures Dr Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), serves on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, and Relypsa, and participates on clinical endpoint committees for studies sponsored by Novartis and the NIH. Laboratory results on admission Reference range* Platelet count (K/L) 217 150-450 D-dimer (ng/mL) >4000